Dr Hari Pujar | Vice President Technical Development and Manufacturing
Moderna Therapeutics | United States

Dr Hari Pujar, Vice President Technical Development and Manufacturing, Moderna Therapeutics

Dr. Hari Pujar is the Vice President of Technical Development and Manufacturing at Moderna Therapeutics, a privately-held RNA therapeutics company.  Previously, he was a Global Product Leader for pediatric and adult vaccine franchises representing over $2B+ in annual revenue in the commercial division of Merck & Co., Inc., with responsibility covering R&D, manufacturing, and commercial strategy.  Earlier, also at Merck, Dr. Pujar managed bioprocess development, external bioprocess R&D, and external cGMP manufacturing of vaccines, novel biologics, and biosimilars, where he contributed to product development from late discovery through commercialization, including global regulatory filings for a number of vaccine and biologics candidates.
He has been active in leadership roles with the American Chemical Society, including serving as the Chair of the Biotechnology Division.  He served as a steering committee member of the EPSRC Innovative Manufacturing Research Center for Bioprocessing and Center for Innovative Manufacturing in Emergent Macromolecular Therapies, both at University College London. He has been adjunt/invited lecturer at University College London, University of Delaware, Johns Hopkins University, Villanova University, Indian Institute of Technology, and Indian Institute of Science.  He has authored numerous peer-reviewed publications and is a co-editor of a book on Vaccine Development and Manufacturing.  He has won the James van Lanen Award of the American Chemical Society and is a Fellow of the American Institute of Medical and Biological Engineering.
He holds a bachelor’s degree in Chemical Engineering from Institute of Chemical Technology, Mumbai, a Ph.D. in Chemical Engineering from the University of Delaware and an MBA in Finance from the Wharton School at the University of Pennsylvania.

Appearances:



DC Co-conference Day 2 April 4 @ 11:40

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

back to speakers